Salud financiera de hoja de balance de Zynex

Salud financiera controles de criterios 5/6

Zynex tiene unos fondos propios totales de $58.6M y una deuda total de $57.4M, lo que sitúa su ratio deuda/fondos propios en 97.9%. Sus activos y pasivos totales son $151.4M y $92.8M respectivamente. Zynex El EBIT de la empresa es de $18.6M, por lo que su ratio de cobertura de intereses es de 22.6. Su tesorería e inversiones a corto plazo ascienden a $52.4M.

Información clave

124.9%

Ratio deuda-patrimonio

US$57.61m

Deuda

Ratio de cobertura de intereses	9.9x
Efectivo	US$44.58m
Patrimonio	US$46.13m
Total pasivo	US$90.78m
Activos totales	US$136.90m

Actualizaciones recientes sobre salud financiera

Recent updates

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Jan 24

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Aug 03

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Mar 30

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Jan 23

Short Squeeze Candidate With Low PEG Ratio: Zynex

Oct 05

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA

Feb 17

Zynex: Turnaround Nears Inevitable End - Largest Payor Cuts TENS Reimbursement, May Eliminate Earnings

Dec 10

Análisis de la situación financiera

Pasivos a corto plazo: ZYXILos activos a corto plazo ($102.9M) de la empresa superan a sus pasivos a corto plazo ($19.8M).

Pasivo a largo plazo: ZYXILos activos a corto plazo ($102.9M) superan a sus pasivos a largo plazo ($73.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ZYXI(8.4%) se considera satisfactoria.

Reducción de la deuda: ZYXIha pasado de 0% a 97.9% en los últimos 5 años.

Cobertura de la deuda: ZYXILa deuda de la empresa está bien cubierta por el flujo de caja operativo (28.5%).

Cobertura de intereses: ZYXILos pagos de intereses de su deuda están bien cubiertos por el EBIT (22.6x cobertura).

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Zynex

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Recent updates

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Zynex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Zynex, Inc. Reiterates Revenue Guidance Full Year 2022

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

First quarter 2022 earnings: EPS misses analyst expectations

Insufficient new directors

Zynex, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Zynex, Inc. Provides Revenue Guidance for the Year 2022

Zynex, Inc., Annual General Meeting, May 19, 2022

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 12%